• Consensus Rating: Buy
  • Consensus Price Target: $28.00
  • Forecasted Upside: 151.80%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$11.12
▼ -0.07 (-0.63%)

This chart shows the closing price for ALMS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alumis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALMS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALMS

Analyst Price Target is $28.00
▲ +151.80% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Alumis in the last 3 months. The average price target is $28.00, with a high forecast of $36.00 and a low forecast of $13.00. The average price target represents a 151.80% upside from the last price of $11.12.

This chart shows the closing price for ALMS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Alumis.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/17/2024

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/17/2024HC WainwrightInitiated CoverageBuy$30.00
8/19/2024Cantor FitzgeraldReiterated RatingOverweight
7/23/2024Leerink PartnrsUpgradeStrong-Buy
7/23/2024Cantor FitzgeraldInitiated CoverageOverweight$13.00
7/23/2024Leerink PartnersInitiated CoverageOutperform$29.00
7/23/2024GuggenheimInitiated CoverageBuy$32.00
7/23/2024Morgan StanleyInitiated CoverageOverweight$36.00
(Data available from 10/17/2019 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/19/2024
  • 7 very positive mentions
  • 9 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
8/18/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/17/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/17/2024

Current Sentiment

  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Alumis logo
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.
Read More

Today's Range

Now: $11.12
Low: $10.80
High: $11.75

50 Day Range

MA: $11.64
Low: $9.74
High: $13.00

52 Week Range

Now: $11.12
Low: $9.54
High: $13.53

Volume

47,485 shs

Average Volume

171,084 shs

Market Capitalization

$518.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Alumis?

The following equities research analysts have issued research reports on Alumis in the last year: Cantor Fitzgerald, Guggenheim, HC Wainwright, Leerink Partners, Leerink Partnrs, and Morgan Stanley.
View the latest analyst ratings for ALMS.

What is the current price target for Alumis?

5 Wall Street analysts have set twelve-month price targets for Alumis in the last year. Their average twelve-month price target is $28.00, suggesting a possible upside of 151.8%. Morgan Stanley has the highest price target set, predicting ALMS will reach $36.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $13.00 for Alumis in the next year.
View the latest price targets for ALMS.

What is the current consensus analyst rating for Alumis?

Alumis currently has 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALMS will outperform the market and that investors should add to their positions of Alumis.
View the latest ratings for ALMS.

What other companies compete with Alumis?

How do I contact Alumis' investor relations team?

Alumis' physical mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080. The company's listed phone number is (650) 231-6625 and its investor relations email address is [email protected]. The official website for Alumis is www.alumis.com. Learn More about contacing Alumis investor relations.